CPA
DFTX

Capital Performance Advisors’s Definium Therapeutics DFTX Stock Holding History

Capital Performance Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80
Closed -$455 – 1682
2024
Q3 		$455 Buy
+80
New +$556 ﹤0.01% 2296

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's DFTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 80 shares — an estimated $455 sold.

Capital Performance Advisors first reported a position in DFTX in Q3 2024 and held it in 1 quarter. The position peaked at $455 in Q3 2024. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 80 Definium Therapeutics shares in Q4 2024, an estimated $455.
  • Capital Performance Advisors first reported a position in Definium Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Definium Therapeutics position peaked at $455 in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.